Design, Synthesis and Development of Novel Antiviral Agents
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 108
Special Issue Editor
Special Issue Information
Dear Colleagues,
The increase in infectious diseases related to emerging viruses (or the re-emergence of old ones) is still a "Hot Topic" nowadays [1]. Over the last four years, we have extensively discussed the most recent advances in the antiviral agents of SARS-CoV-2 and related coronaviruses (SARS and MERS). However, it is essential to underline that many other viruses are dangerous to human health. In this regard, the World Health Organization (WHO) released a list of pathogens that could cause future pandemics and outbreaks, recommending the scientific community to invest in research [2,3]. From this perspective, it is appropriate to keep up with and underline the progress made to date in the Design and Synthesis of new antiviral drugs, as well as the importance of in silico computational methodologies in the Development of antiviral drug discovery.
This Special Issue aims to collect original contributions and reviews that delve into the most recent research results related to the Design, Synthesis and Development of Novel Antiviral Agents to overcome the emergency of future viral outbreaks.
We welcome original research, review, mini-review and perspective articles on themes including, but not limited to, the following:
- Rational design and synthesis;
- In silico drug design;
- Multi-target rational drug design;
- Drug repurposing proposals;
- Machine learning and deep learning in drug design in the antiviral field.
We invite authors to submit original manuscripts addressing all aspects of this topic.
References
- De Clercq E. Antivirals: Past, present and future. Biochem Pharmacol. 2013, 85, 727–744. doi:10.1016/j.bcp.2012.12.011.
- www.who.int/news/item/21-11-2022-who-to-identify-pathogens-that-could-cause-future-outbreaks-and-pandemics.
- www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts.
Dr. Antonio Lupia
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viruses
- emerging viral diseases
- infectious diseases
- antiviral agents
- small molecules
- structure−activity relationship (SAR) studies
- drug design (DD) and synthesis
- computer-aided drug discovery (CADD)
- medicinal chemistry
